J&J still plans to scale up Carvyk­ti man­u­fac­tur­ing this year as it awaits FDA de­ci­sion on ex­pan­sion to ear­li­er lines

John­son & John­son tout­ed “sig­nif­i­cant progress” in man­u­fac­tur­ing Carvyk­ti, the CAR-T ther­a­py it de­vel­oped with Leg­end Biotech, af­ter hav­ing to find ways to im­prove pro­duc­tion last year.

“We feel good that we are pro­gress­ing with Carvyk­ti and that we will con­tin­ue to de­liv­er quar­ter-over-quar­ter growth in 2024,” CEO Joaquin Du­a­to said Tues­day morn­ing dur­ing an in­vestor call.

Dur­ing the com­pa­ny’s last earn­ings call in Oc­to­ber, J&J said that it has been work­ing to in­crease man­u­fac­tur­ing ca­pac­i­ty, both in­ter­nal­ly and through a part­ner­ship with No­var­tis to meet de­mand. The com­pa­ny has al­so not­ed that the as­set’s lentivirus com­po­nent was a pro­duc­tion bot­tle­neck.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER